CSF-1R inhibitor and its use
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- MYROBALAN THERAPEUTICS INC
- Filing Date
- 2023-06-14
- Publication Date
- 2026-06-22
AI Technical Summary
There is a need for novel CSF-1R inhibitors that effectively inhibit CSF-1R activity while selectively targeting it over other kinases, such as cKit, FLT3, and PDGFR-β, and have a favorable pharmacokinetic profile and high brain exposure, to treat diseases like cancer, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases.
Development of compounds of formula (I) and their pharmaceutically acceptable salts, which selectively inhibit CSF-1R, have a desired pharmacokinetic profile, and exhibit high exposure across the blood-brain barrier.
The compounds effectively inhibit CSF-1R activity, providing therapeutic benefits in treating conditions mediated by CSF-1R, including autoimmune diseases, inflammatory diseases, and neurodegenerative diseases, with enhanced brain penetration.
Smart Images
Figure 00000000_0000_ABST